Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens

Vaccine

Volumn 18, Issue 11-12, 2000, Pages 1031-1039

  Zeng, Weiguang ^a   Jackson, David C ^a   Murray, Julie ^a   Rose, Keith ^b   Brown, Lorena E ^a  

^a Department of Civil and Environmental Engineering   (Australia)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Lipid; Peptide; Polyoxime

Indexed keywords

ANTIGEN; FREUND ADJUVANT; OXIME DERIVATIVE; POLYOXIME DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG SYNTHESIS; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; VACCINATION;

ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; INJECTIONS, INTRAPERITONEAL; LIPIDS; LUNG; LYMPH NODES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; OXIMES; PEPTIDES;

EID: 0033990731     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00346-1     Document Type: Article

References (33)

1. Tam J.P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA. 85:1988;5409-5413.
2. Wuensch E., Moroder L., Huebner G., Musiol H.-J., von Gruenigen R., Goehringen W., Scharf R., Schneider C.H. Fully synthetic immunogens. Int. J. Pept. Protein Res. 37:1991;90-102.
3. Drijfhout J.W., Bloemhoff W. A new synthetic functionalized antigen carrier. Int. J. Pept. Protein Res. 37:(1):1991;27-32.
4. Rose K., Zeng W., Brown L.E., Jackson D.C. A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Mol. Immunol. 32:1995;1031-1037.
5. Defoort J.P., Nardelli B., Huang W., Ho D.D., Tam J.P. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc. Natl. Acad. Sci. USA. 89:(9):1992;3879-3883.
6. Defoort J.P., Nardelli B., Huang W., Tam J.P. A rational design of synthetic peptide vaccine with a built-in adjuvant: a modular approach for unambiguity. Int. J. Pept. Protein Res. 40:(3/4):1992;214-221.
7. Nardelli B., Haser P.B., Tam J.P. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine. 12:(14):1994;1335-1339.
8. Tam J.P., Spetzler J.C. Chemoselective approaches to the preparation of peptide dendrimers and branched artificial proteins using unprotected peptides as building blocks. Biomed. Pept. Protein Nucleic Acids. 1:1995;123-132.
9. Wilken J., Kent S.B. Chemical protein synthesis. Curr. Opin. Biotechnol. 9:(4):1998;412-426.
10. Wallace C.J. Peptide ligation and semisynthesis. Curr. Opin. Biotechnol. 6:(4):1995;403-410.
11. Rose K. Facile synthesis of artificial protein. J. Am. Chem. Soc. 116:1994;30-33.
12. Zeng W., Rose K., Jackson D.C. Peptide engineering for vaccines through polyoxime chemistry. Epton R. Innovation and perspectives in solid phase synthesis: peptides, proteins, and nucleic acids, biological and biomedical applications. 1996;567-572 Mayflower Worldwide, Birmingham, UK.
13. Rose K., Zeng W., Dragovic M., Brown L.E., Jackson D.C. Polyoxime artificial protein as vaccines. Kaumaya P.T.P., Hodges R.S. Peptides: Chemistry and Biology, Proceedings of the 14th American Peptide Symposium. 1996;767-769 Mayflower Worldwide, Birmingham, UK.
14. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Clavijo P., Nussenzweig R., Simon R., Zeng W., Rose K. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine. 16:(6):1998;590-600.
15. Zeng W., Jackson D.C., Rose K. Synthesis of a new template with a built-in adjuvant and its use in constructing peptide vaccine candidates through polyoxime chemistry. J. Pept. Sci. 2:(1):1996;66-72.
16. Jung G., Bessler W.G. Lipopeptides as adjuvants and integrated adjuvanticity. Zegers N.D., Boersma W.J.A., Claaasen E. Immunological recognition of peptides in medicine and biology. 1995;159-168 CRC Press, Boca Raton, New York, London, Tokyo.
17. Deres K., Schild H., Wiesmuller K.H., Jung G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:(6249):1989;561-564.
18. Jackson D.C., Brown L.E. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen. Pept. Res. 4:(3):1991;114-124.
19. Wiesmueller K-H., Bessler W., Jung G. Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe-Seyler's Z. Physiol. Chem. 364:1983;593-606.
20. Zeng W., Regamey P.O., Rose K., Wang Y., Bayer E. Use of Fmoc-N-(2-hydroxy-4-methoxybenzyl)amino acids in peptide synthesis. J. Pept. Res. 49:(3):1997;273-279.
21. Quibell M., Turnell W.G., Johnson T. Preparation and purification of β-amyloid (1-43) via soluble, amide backbone protected intermediates. J. Org. Chem. 59:1994;1745-1750.
22. Quibell M., Packman L.C., Johnson T. Synthesis of the 3-repeat region of human tau-2 by solid phase assembly of backbone amide-protected segments. J. Am. Chem. Soc. 117:1995;11656-11668.
23. Brown L.E., Murray J.M., Anders E.M., Tang X.L., White D.O., Tregear G.W., Jackson D.C. Genetic control and fine specificity of the immune response to a synthetic peptide of influenza virus hemagglutinin. J. Virol. 62:(5):1988;1746-1752.
24. Deliyannis G., Jackson D.C., Dyer W., Bates J., Coulter A., Harling-McNabb L., Brown L.E. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine. 16:(20):1998;2058-2068.
25. Mora A.L., Tam J.P. Controlled lipidation and encapsulation of peptides as useful approach to mucosal immunisations. J. Immunol. 161:1998;3616-3623.
26. Martinon F., Gras-Masse H., Boutillon C., Chirat F., Deprez B., Guillet J.G., Gomard E., Tartar A., Levy J.P. Immunization of mice with lipopeptides bypasses the requisite for adjuvant. J. Immunol. 149:1992;3416-3422.
27. Deprez B., Sauzet J.P., Boutillon C., Martinon F., Tartar A., Sergheraert C., Guillet J.G., Gomard E., Gras-Masse H. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine. 14:1996;375-382.
28. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., Yuan L., Chisari F., Furze J., Barholomeuz, Chesnut R.W. Development of a lipopeptide-based therapeutic Vaccine to treat chronic HBV infection. J. Clin. Invest. 959:(1):1995;341-349.
29. BenMohamed L., Gras-Masse H., Tartar A., Daubersies P., Brahimi K., Bossus M., Thomas A., Druilhe P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:(5):1997;1242-1253.
30. Huang W., Nardelli B., Tam J.P. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Mol. Immunol. 31:(15):1994;1191-1199.
31. Livingston B.D., Crimi C., Grey H., Ishioka G., Chisari F.V., Fikes J., Chesnut R.W., Sette A. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1997;1383-1392.
32. Sauzet J.P., Deprez B., Martinon F., Guillet J.G., Gras-Masse H., Gomard E. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine. 13:1995;1339-1345.
33. Calvo-Calle J.M., de Oliveira G.A., Clavijo P., Maracic M., Tam J.P., Lu Y.A., Nardin E.H., Nussenzweig R.S., Cochrane A.H. Immunogenicity of multiple antigen peptides containing B and nonrepeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum. J. Immunol. 150:1993;1403-1412.